Also notable is a minimal change in expression of the chemokine CXCR3 but a significant increase in the expression of its ligands, CXCL10 and CXCL11, which are important in activating other signaling molecules that recruit immune cells for the general enhancement of anti-tumor pathways. The gene discussed is CXCR3; the disease is neoplasm.